Wockhardt share news and announcements
NSE: WOCKPHARMABSE: 532300Pharmaceuticals & BiotechnologySmall Cap
Last close ₹1,801.70down ₹53.80 (2.90%)BSE ₹1,801.25
Share price at the NSE close on 23 Oct 2026. Previous close ₹1,855.50.
52-week range of traded prices to 23 Oct 2026
₹1,086.70Low, 23 Mar 2026₹2,422.30High, 1 Jun 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹29,276 Cr311th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- 71.6
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- 5.9
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 8.8%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 7.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.40
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 8,79,19043.6% delivered
Wockhardt share news and announcements
1,008 announcements, routine notices left out, newest first. Page 10 of 21.
Aug 2018
4 Aug · Board meeting
1 Aug · Legal
Exchange has sought clarification from Wockhardt Limited with respect to announcement dated 29-Jul-2018, regarding " Wockhardt Limited has informed the Exchange regarding a press release dated July 29, 2018, titled "Wockhardt sets up its first manufacturing and R&D unit in Middle East".". On basis of above the Company is required to clarify following: 1. Rationale. 2. Mode of financing; 3. Investment required; 4. Period within which the proposed capacity is to be added; 5. Proposed capacity addition; The response of the Company is awaited.
Jul 2018
Jun 2018
27 Jun · Meeting
15 Jun · Disclosure
May 2018
8 May · Meeting
4 May · Declaration for audit reports with unmodified opinion(s)
4 May · Board meeting
Apr 2018
27 Apr · Legal
Exchange has sought clarification from the Company with respect to news item captioned- "Wockhardt under lens for tweaking dosage of essential medicine" In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company is aware of any information that has not been announced to the Exchanges under regulation 30 of Listing Regulations. The response from the Company is awaited.11 Apr · Meeting
Mar 2018
Feb 2018
19 Feb · Legal
Exchange has sought clarification from Wockhardt Limited with respect to announcement dated 15-Feb-2018, regarding " Wockhardt Limited has informed the Exchange regarding Credit Rating: CARE Ratings Limited (CARE Ratings) has revised the Company's Rating for Long - Term Bank Facilities (Fund Based Working Capital limit) as CARE A+; Outlook: Stable from earlier it was CARE AA-; Outlook: Negative and Short Term Bank Facilities (Non Fund Based Working Capital limit) as CARE A1 from CARE A1+. Further, CARE Ratings has also revised rating for the proposed issue of NCDs for an amount of Rs. 250 crore of the Company as CARE A+; Outlook: Stable from earlier it was CARE AA-; Outlook: Negative.". On basis of above the Company is required to clarify following: 1. In case of downward rating, the disclosure may include reasons published by rating agency for such downward rating.The response of the Company is awaited.16 Feb · Disclosure
12 Feb · Meeting
Jan 2018
30 Jan · Legal
Exchange has sought clarification from Wockhardt Limited with respect to announcement dated 29-Jan-2018, regarding " Wockhardt Limited has informed the Exchange regarding Outcome of Board Meeting held on January 29, 2018. On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment);The response of the Company is awaited.
Nov 2017
Oct 2017